With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Todyl, an industry-leading cybersecurity platform, today announced a new partnership with RSA, the security-first identity leader. The partnership began with RSA selecting Todyl to protect its ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

OmniOn Powertm (OmniOn) has announced the appointment of Philip Zuk as its new Senior Vice President and General Manager of its AI and Data Center business. With more than 25 years of experience in ...

Top financial stories include CK Hutchison discussing selling Three Ireland to Liberty Global, GSK acquiring Rapt ...

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology: Daejeon, South Korea Wednesday, January 21, 2026, ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, ...

Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, ...

Alteogen and Tesaro, a subsidiary of GSK, have entered an exclusive license agreement concerning a subcutaneous formulation of dostarlimab.

RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.